recent articles
Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have...
New Mexico, USA 12/2/2014 - Indica Labs announced today that its HALO™ image analysis platform was used to quantify predictive biomarkers in a ground breaking study of the melanoma drug, pembrolizumab. Pembrolizumab is an immunotherapy...
© 2023 Tissuepathology.com. All rights reserved. Millennial Consulting. | Web Design by Zealth Digital Marketing